The goal of this clinical trial is to test the effect of multiple micronutrient supplements in reducing anemia in women of reproductive age in comparison with iron-folic acid. The main questions it aims to answer are: * What is the effect of multiple micronutrient supplements in reducing anemia among women of reproductive age in comparison with iron-folic acid? * What is the effect of multiple micronutrient supplements in reducing iron deficiency among women of reproductive age in comparison with iron-folic acid? Participants will * be given multiple micronutrient supplements, iron folic acid, or placebo twice weekly for 17 weeks * be asked to respond to the interview * provide blood, urine, and stool samples Researchers will compare the control group with the intervention groups to see the effect of multiple micronutrient supplements on iron deficiency and anemia reduction.
Women in developing countries are often at risk of micronutrient deficiencies due to inadequate micronutrient intake. Since various micronutrient deficiencies co-exist, multiple micronutrient supplements are recommended to combat their deficiencies. The purpose of this study is to assess the effects of multiple micronutrient supplements among women of reproductive age in reducing anemia compared with iron-folic acid as currently practiced in Ethiopia. The current study is a community-based individual randomized placebo-controlled trial. The trial is double blinded with three parallel groups. This trial will be conducted in three randomly selected kebeles (villages) in the Kebribeyah district in the Somali regional state. The sample size determined for this study is 305. There will be two intervention arms and one control arm in this trial. A third of participants will be in each arms. The intervention arms will will be supplemented with United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) or iron-folic acid (IFA) and the control arm with placebos twice a week. The investigators will follow the study participants for 17 weeks. The primary outcome is a change in mean hemoglobin concentrations and reduction in anemia prevalence. Stratified randomization will be used to assign the participants randomly to the study arms. In the current trial, the outcome assessors and study subjects will both be blinded. The supplements being administered to participants, as well as who is in the intervention group and who is in the control group, will be masked from the assessors. The trial participants will be blinded to the kind of supplements being administered to them or the group to which they were assigned. The allocation sequence of participants will be concealed from the researcher who will assign the participants to the study arms. When the eligible woman meets the screening criteria and gives informed consent, she will be assigned an envelope that contains an allocation sequence. As outcome measures, the investigators will assess the reduction in overall anemia and iron deficiency anemia attributable to the supplementation. In addition, a complete blood count (CBC) will be tested for all study participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
265
The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
Ethiopian Public Health Institute
Addis Ababa, Addis Ababa, Ethiopia
Change in mean hemoglobin concentrations among women of reproductive age
Hemoglobin concentration is measured in gram/deciliter from whole blood samples collected at baseline and end-line.
Time frame: Blood sample will be collected once at baseline and once at end-line in four months
Change in overall anemia among women of reproductive age
Anemia diagnosed when hemoglobin concentration test result is less than 12 g/dl
Time frame: Blood sample will be collected once at baseline and once at end-line in four months
Change in mean ferritin concentration among women of reproductive age
Ferritin concentration is measured from serum ferritin in µg/L.
Time frame: The serum samples will be collected once at the baseline and once at the end-line in four months
Change in iron deficiency anemia among women of reproductive age
Iron deficiency anemia is diagnosed when hemoglobin concentration test result is less than 12 g/dl and the ferritin concentration test result is less than 15 µg/L
Time frame: Blood sample will be collected once at baseline and once at end-line in four months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.